Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
By G. Folprecht, T. Gruenberger, W. Bechstein, H. Raab, F. Lordick, J. Hartmann, H. Lang, A. Frilling, J. Stoehlmacher, J. Weitz and 8 more. The Lancet Oncology, 2010
996 citations recorded by the source corpus.
Subfields: Hepatology, Oncology
View Paper: https://www.semanticscholar.org/paper/65cca1c833ad229936da812152f5e5f8cc73f2b1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hepatology
In Oncology
Citations in the corpus
- Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial (2017, background): “Compared with figures in the literature for patients with liver-only disease, this percentage is relatively low and may reflect the unfavorable anatomic locations of the lesions at random assignment, which is not influenced by systemic treatment (5,6).”
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, methodology): “Folprecht G, Gruenberger T, Bechstein W et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).”